Myriad Genetics announced its support for the first evidence-based expanded carrier screening practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors, NSGC, in the Journal of Genetic Counseling. NSGC’s guidelines support equitable access and care to all patients looking to start or grow their families by recommending that "ECS be made available for all individuals considering reproduction and all pregnant reproductive pairs."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics sees FY23 (40c)-(20c), consensus (30c)
- Myriad Genetics sees Q1 EPS (20c)-(18c), consensus (10c)
- Myriad Genetics reports Q4 EPS (12c), consensus (16c)
- Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
- Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023